Advertisement
Advertisement
NBIX
Neurocrine Biosciences Inc
161.50
USDSponsored
-4.56
-2.75%
Aug 05, 15:59 UTC -4
Closed
Pre-Market
163.91
+2.41
+1.49%
NBIX Earnings Reports
Positive Surprise Ratio
NBIX beat 19 of 42 last estimates.
45%
Next Report
Date of Next Report
Oct 26, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.00B
/$2.17
Implied change from Q2 26 (Revenue/ EPS)
+4.79%
/-23.86%
Implied change from Q3 25 (Revenue/ EPS)
+26.42%
/+6.37%
Neurocrine Biosciences Inc earnings per share and revenue
On Jul 30, 2026, NBIX reported earnings of 2.85 USD per share (EPS) for Q2 26, beating the estimate of 1.03 USD, resulting in a 175.31% surprise. Revenue reached 959.00 million, compared to an expected 1.03 billion, with a -7.33% difference. The market reacted with a -10.08% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 18 analysts forecast an EPS of 2.17 USD, with revenue projected to reach 1.00 billion USD, implying an decrease of -23.86% EPS, and increase of 4.79% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
BeOne Medicines Ltd. - ADR
Report Date
Aug 05, 2026 For Q2 26
Estimate
-Actual
$13.83
Surprise
-
United Therapeutics Corp
Report Date
Aug 05, 2026 For Q2 26
Estimate
$6.96
Actual
$7.27
Surprise
+4.32%
Stevanato Group S.p.A.
Report Date
Aug 04, 2026 For Q2 26
Estimate
$0.13
Actual
$0.13
Surprise
+6.83%
BioCryst Pharmaceuticals Inc
Report Date
Aug 05, 2026 For Q2 26
Estimate
$0.12
Actual
$0.30
Surprise
+148.14%
Xencor, Inc.
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$0.85
Actual
-$0.28
Surprise
+65.93%
Bioventus Inc. Class A Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
$0.21
Actual
$0.22
Surprise
+0.82%
Zevra Therapeutics, Inc. Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
$0.10
Actual
$0.25
Surprise
+128.31%
Akebia Therapeutics, Inc.
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$0.04
Actual
-$0.02
Surprise
+55.46%
USANA Health Sciences Inc
Report Date
Aug 04, 2026 For Q2 26
Estimate
$0.43
Actual
-$0.07
Surprise
-115.96%
Cumberland Pharmaceuticals Inc
Report Date
Aug 04, 2026 For Q2 26
Estimate
-Actual
-$0.20
Surprise
-
FAQ
What were Neurocrine Biosciences Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Neurocrine Biosciences Inc reported EPS of $2.85, beating estimates by 175.31%, and revenue of $959.00M, -7.33% below expectations.
How did the market react to Neurocrine Biosciences Inc's Q2 2026 earnings?
The stock price moved down -10.08%, changed from $185.50 before the earnings release to $166.80 the day after.
When is Neurocrine Biosciences Inc expected to report next?
The next earning report is scheduled for Oct 26, 2026.
What are the forecasts for Neurocrine Biosciences Inc's next earnings report?
Based on 18
analysts, Neurocrine Biosciences Inc is expected to report EPS of $2.17 and revenue of $1.00B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement